Tiziana or the
Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ( Ordinary Shares ) on the standard listing segment of the Official List of the Financial Conduct Authority ( FCA ) (the Official List ) and admission to trading on the London Stock Exchange plc s (the London Stock Exchange ) main market ( Main Market ) for listed securities (together, Admission ). The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company.
Pursuant to AIM Rule 41 of the AIM Rules for Companies, the Company hereby gives notice of the intended cancellation of trading of its Ordinary Shares on the AIM market of the London Stock Exchange ( AIM ).
London, New York, 17 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ( Ordinary Shares ) on the standard listing segment of the Official List of the Financial Conduct Authority ( FCA ) (the Official List ) and admission to trading on the London Stock Exchange plc s (the London Stock Exchange ) main market ( Main Market ) for listed securities (together, Admission ). The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company.